Redefining the Landscape: Acquired Mutations Driving Systemic Autoinflammatory Diseases
Arthritis & Rheumatology · 19.08.2026
DOI: 10.1002/art.70282 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis & Rheumatology, online erschienen am 19.08.2026. Verfasst von Dorota Rowczenio und 8 weiteren Autor:innen. Beteiligte Einrichtung: National Amyloidosis Centre, Division of Infection, Immunity, and Rare Diseases, Royal Free London NHS Foundation Trust, London, United Kingdom. Die Arbeit nennt 43 Literaturangaben.
Abstract (Originalsprache)
Objective
Mosaicism is a recognized cause of systemic autoinflammatory diseases (SAIDs). Initially described in cryopyrin‐associated periodic syndromes (CAPS), it has since been reported in several dominantly inherited SAIDs, including Blau syndrome, tumor necrosis factor receptor–associated periodic syndrome (TRAPS), stimulator of interferon genes–associated vasculopathy with onset in infancy, NLRC4 inflammasomopathies, and familial Mediterranean fever. Recently, somatic variants underlying vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic syndrome (VEXAS syndrome) have extended this to late‐onset disease. This study aimed to characterize the prevalence, spectrum, and clinical significance of acquired variants in SAIDs.
Methods
A total of 5,530 patients referred to a national SAIDs reference center between 2017 and 2025 underwent deep next‐generation sequencing autoinflammatory gene panel testing to detect low‐level mosaicism. Results underwent multidisciplinary review and correlation with clinical data from electronic medical records.
Results
SAID diagnoses were made in 403 of 5,530 patients (7.3%, 95% confidence interval [CI] 6.6%–8.0%). Among these, mosaic variants were identified in 83 patients (20.6%, 95% CI 16.9%–24.8%), including patients with VEXAS syndrome (69%), CAPS (24%), TRAPS (5%), Blau syndrome (1%), and NLRC4 inflammasomopathies (1%). Twenty‐three distinct mosaic variants were identified across different SAIDs genes; in eight, the minor allele frequency was ≤5%. We report the first case of vertical transmission of TRAPS due to gonosomal mosaicism. AA amyloidosis complicated the disease course in 20% of patients diagnosed with late‐onset mosaic CAPS.
Conclusion
Somatic mosaicism is a frequent mechanism underlying late‐onset SAIDs, which are often diagnosed late and carry a high risk of AA amyloidosis. To our knowledge, this represents the largest genetically heterogeneous single‐center cohort of individuals with mosaic SAIDs reported to date.
Autor:innen und Institutionen
- National Amyloidosis Centre, Division of Infection, Immunity, and Rare Diseases, Royal Free London NHS Foundation Trust, London, United Kingdom.
- Paediatric Rheumatology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom.
ORCID-Profile: Dorota Rowczenio, Claire J Peet
Zitieren
APA
Rowczenio, D., Omoyinmi, E., Brown, J., Kamara, K., Guarniere, S., Peet, C. J., Hawkins, P. N., Papadopoulou, C., & Lachmann, H. J. (2026). Redefining the Landscape: Acquired Mutations Driving Systemic Autoinflammatory Diseases. Arthritis & Rheumatology. https://doi.org/10.1002/art.70282
Vancouver
Rowczenio D, Omoyinmi E, Brown J, Kamara K, Guarniere S, Peet CJ, et al. Redefining the Landscape: Acquired Mutations Driving Systemic Autoinflammatory Diseases. Arthritis & Rheumatology. 2026. doi:10.1002/art.70282
BibTeX
@article{Rowczenio2026,
author = {Rowczenio, Dorota and Omoyinmi, Ebun and Brown, Jake and Kamara, Kadiatu and Guarniere, Sophia and Peet, Claire J and Hawkins, Philip N and Papadopoulou, Charalampia and Lachmann, Helen J},
title = {Redefining the Landscape: Acquired Mutations Driving Systemic Autoinflammatory Diseases},
journal = {Arthritis & Rheumatology},
year = {2026},
doi = {10.1002/art.70282}
}
EUVIMED